Medical device firm Angiotech Pharmaceuticals of Vancouver, British Columbia, received confirmation in the U.K. of the validity of one of its patents related to its paclitaxel stent inventions, the company said.
The patent at issue was granted to Angiotech by the European Patent Office (EPO) in 1997. At the EPO, five different companies opposed the patent. After more than nine years of legal battles, the validity of the patent was maintained in a decision by the House of Lords.
In 2005, Angiotech filed suit against Conor Medsystems in the Netherlands; Conor responded by commencing proceedings in the U.K. to revoke the patent. The House of Lords decision ends this suit, according to Angiotech.
Copyright © 2008 AuntMinnie.com